Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
ClinicalTrials.gov Medical Disclaimer This article is for educational and informational purposes only
10.1016/j.bionut.2011.11.001 164 RibeiroM
Positive Phase 2b Proof-of-Concept Data: In December 2025, Kallyope announced positive results from the randomized, double-blinded, placebo-controlled, Phase 2b dose-ranging study of elismetrep, with a design consistent with FDA guidance on migraine studies that analyzed performance across key measures standard for the clinical assessment of migraine medications
These findings suggest that GLP-1 receptor agonists may offer a critical advantage in managing diabetes and cardiovascular risk in patients with inflammatory arthritis, said Antonio Avia-Zubieta, Senior Scientist at Arthritis Research Canada and Principal Investigator in this study
US$ 25.29
US$ 21.15
US$ 20.68
US$ 23.30
US$ 29.95
US$ 22.29
US$ 25.09
